JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on August 10, 2004; DOI: 10.1124/jpet.104.071803


0022-3565/04/3113-996-1007$20.00
JPET 311:996-1007, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.071803v1
311/3/996    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Polasek, T. M.
Right arrow Articles by Miners, J. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Polasek, T. M.
Right arrow Articles by Miners, J. O.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CARBON MONOXIDE
*TAXOL
*TESTOSTERONE

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Mechanism-Based Inactivation of Human Cytochrome P4502C8 by Drugs in Vitro

Thomas M. Polasek, David J. Elliot, Benjamin C. Lewis, and John O. Miners

Department of Clinical Pharmacology, Flinders University and Flinders Medical Centre, Adelaide, Australia

Studies were conducted to evaluate the potential mechanism-based inactivation of recombinant and human liver microsomal CYP2C8 by clinically used drugs. Several tricyclic antidepressants, calcium channel blockers, monoamine oxidase inhibitors, and various other known CYP3A4 inhibitors exhibited greater inhibition of CYP2C8 (paclitaxel 6{alpha}-hydroxylation) following preincubation, consistent with mechanism-based inactivation. Inactivation of recombinant CYP2C8 by phenelzine, amiodarone, verapamil, nortriptyline, fluoxetine, and isoniazid was of the pseudo-first order type and was characterized by respective inactivation kinetic constants (KI and kinact) of 1.2 µM and 0.243 min–1, 1.5 µM and 0.079 min–1, 17.5 µM and 0.065 min–1, 49.9 µM and 0.036 min–1, 294 µM and 0.083 min–1, and 374 µM and 0.042 min–1. Spectral scanning of recombinant CYP2C8 demonstrated the formation of metabolite-intermediate complexes with verapamil, nortriptyline, fluoxetine, and isoniazid, but not amiodarone. In contrast, inactivation by phenelzine resulted from heme destruction by free radicals. Studies with human liver microsomes (HLMs) revealed that nortriptyline, verapamil, and fluoxetine were not mechanism-based inactivators (MBIs) of CYP2C8. Simultaneous inactivation of CYP2C8 and CYP3A4 (paclitaxel 3'-phenyl-hydroxylation) was observed using amiodarone, isoniazid, and phenelzine with the efficiency of inactivation greater for the CYP3A4 pathway. With the exception of phenelzine, glutathione and superoxide dismutase failed to protect CYP2C8 (recombinant and HLMs) or CYP3A4 from inactivation by MBIs. However, the alternate CYP2C8 substrate, torsemide, prevented CYP2C8 inactivation in all cases. These data are consistent with mechanism-based inactivation of CYP2C8 by a range of commonly prescribed drugs, several of which have been implicated in clinically important drug-drug interactions.


Received May 23, 2004; accepted August 6, 2004.

Address correspondence to: Professor John O. Miners, Department of Clinical Pharmacology, Flinders University and Flinders Medical Centre, Bedford Park, Adelaide, South Australia 5042, Australia. E-mail: john.miners{at}flinders.edu.au




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
S. W. Grimm, H. J. Einolf, S. D. Hall, K. He, H.-K. Lim, K.-H. J. Ling, C. Lu, A. A. Nomeir, E. Seibert, K. W. Skordos, et al.
The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America
Drug Metab. Dispos., July 1, 2009; 37(7): 1355 - 1370.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
R. S. Obach, R. L. Walsky, and K. Venkatakrishnan
Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions
Drug Metab. Dispos., February 1, 2007; 35(2): 246 - 255.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. L. Polsky-Fisher, H. Cao, P. Lu, and C. R. Gibson
EFFECT OF CYTOCHROMES P450 CHEMICAL INHIBITORS AND MONOCLONAL ANTIBODIES ON HUMAN LIVER MICROSOMAL ESTERASE ACTIVITY
Drug Metab. Dispos., August 1, 2006; 34(8): 1361 - 1366.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. Atkinson, J. R. Kenny, and K. Grime
AUTOMATED ASSESSMENT OF TIME-DEPENDENT INHIBITION OF HUMAN CYTOCHROME P450 ENZYMES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ANALYSIS
Drug Metab. Dispos., November 1, 2005; 33(11): 1637 - 1647.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.